MX2022011407A - Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda. - Google Patents

Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda.

Info

Publication number
MX2022011407A
MX2022011407A MX2022011407A MX2022011407A MX2022011407A MX 2022011407 A MX2022011407 A MX 2022011407A MX 2022011407 A MX2022011407 A MX 2022011407A MX 2022011407 A MX2022011407 A MX 2022011407A MX 2022011407 A MX2022011407 A MX 2022011407A
Authority
MX
Mexico
Prior art keywords
myeloid leukemia
acute myeloid
compounds
treating
inhibiting recurrence
Prior art date
Application number
MX2022011407A
Other languages
English (en)
Spanish (es)
Inventor
Zhixiong Ye
Michael Serrano-Wu
Kejia Ding
Original Assignee
Flash Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flash Therapeutics Llc filed Critical Flash Therapeutics Llc
Publication of MX2022011407A publication Critical patent/MX2022011407A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2022011407A 2020-03-16 2021-03-15 Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda. MX2022011407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/079464 WO2021184154A1 (en) 2020-03-16 2020-03-16 Compounds for treating or inhibiting recurrence of acute myeloid leukemia
PCT/US2021/022322 WO2021188417A1 (en) 2020-03-16 2021-03-15 Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
MX2022011407A true MX2022011407A (es) 2022-10-13

Family

ID=77767943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011407A MX2022011407A (es) 2020-03-16 2021-03-15 Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda.

Country Status (15)

Country Link
US (1) US11963960B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121430A4 (cg-RX-API-DMAC7.html)
JP (1) JP7744358B2 (cg-RX-API-DMAC7.html)
KR (1) KR102990081B1 (cg-RX-API-DMAC7.html)
CN (1) CN115298180B (cg-RX-API-DMAC7.html)
AR (1) AR121570A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020436612A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018345A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168988A1 (cg-RX-API-DMAC7.html)
IL (1) IL296296A (cg-RX-API-DMAC7.html)
MX (1) MX2022011407A (cg-RX-API-DMAC7.html)
PE (1) PE20230461A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552169A1 (cg-RX-API-DMAC7.html)
TW (1) TWI899184B (cg-RX-API-DMAC7.html)
WO (2) WO2021184154A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
AU2021289345A1 (en) * 2020-06-08 2023-01-19 Halia Therapeutics, Inc. Inhibitors of NEK7 kinase
CN114075190A (zh) 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂
CN113861179A (zh) * 2021-10-22 2021-12-31 上海应用技术大学 一种新型flt3激酶抑制剂及其合成与应用
WO2025124429A1 (zh) * 2023-12-11 2025-06-19 北京康辰药业股份有限公司 芳香胺化合物及其药物组合物、应用
WO2025151010A1 (ko) * 2024-01-11 2025-07-17 주식회사 펠레메드 신규한 피롤로트리아진 유도체 및 이의 용도
KR20250157634A (ko) 2024-04-29 2025-11-05 대한민국(질병관리청 국립보건연구원장) Bax 활성제를 유효성분으로 포함하는 항-hiv-1 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808281A (pt) 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
NZ510588A (en) 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
MXPA03008560A (es) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2005074603A2 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
US7772231B2 (en) 2005-12-29 2010-08-10 Abbott Laboratories Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
JP6327713B2 (ja) 2012-07-27 2018-05-23 国立研究開発法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
USRE48175E1 (en) * 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US10266535B2 (en) 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
US20190255056A1 (en) 2016-09-15 2019-08-22 Riken A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia
CN118027041A (zh) * 2019-05-31 2024-05-14 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
AU2020301399B2 (en) 2019-06-24 2025-12-18 Dana-Farber Cancer Institute, Inc. HCK degraders and uses thereof
CN114746095B (zh) 2019-10-08 2025-01-24 达纳-法伯癌症研究所有限公司 Hck作为myd88突变疾病的治疗靶点
MX2022008148A (es) * 2020-01-02 2022-07-21 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de btk.
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Also Published As

Publication number Publication date
CN115298180A (zh) 2022-11-04
PH12022552169A1 (en) 2024-01-29
JP2023518035A (ja) 2023-04-27
EP4121430A1 (en) 2023-01-25
CA3168988A1 (en) 2021-09-23
WO2021184154A1 (en) 2021-09-23
AU2021239828A1 (en) 2025-04-03
KR102990081B1 (ko) 2026-07-10
BR112022018345A2 (pt) 2022-11-08
AR121570A1 (es) 2022-06-15
WO2021188417A1 (en) 2021-09-23
US20210299128A1 (en) 2021-09-30
TW202200583A (zh) 2022-01-01
JP7744358B2 (ja) 2025-09-25
AU2020436612A1 (en) 2022-09-01
AU2021239828B2 (en) 2025-06-26
TWI899184B (zh) 2025-10-01
US11963960B2 (en) 2024-04-23
PE20230461A1 (es) 2023-03-14
IL296296A (en) 2022-11-01
CN115298180B (zh) 2025-06-10
KR20220154164A (ko) 2022-11-21
EP4121430A4 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
PH12022552169A1 (en) Compounds for treating or inhibiting recurrence of acute myeloid leukemia
MY206478A (en) Inhibitors of sarm1
ZA202301801B (en) Inhibitors of sarm1
MX2025015502A (es) Inhibidores del oncogén de sarcoma de rata de kirsten (kras)
MX2023013912A (es) Metodos para inhibir ras.
MX2024005228A (es) Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
CR20230057A (es) Compuestos tríciclicos de urea como inhibidores de jak2 v617f
CR20230103A (es) Análogos de rapamicina ligados a c40, c28 y c32 como inhibidores de mtor
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
EP4674415A3 (en) Azaquinolines as inhibitors of cd38
MX2023004373A (es) Metodos y composiciones para la degradacion dirigida de proteinas.
MX2024004993A (es) Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2022012329A (es) Compuestos de pirazolilpropanamida y usos de los mismos para el tratamiento de cáncer de próstata.
MX2024003713A (es) Usos de moleculas de union al antigeno multiespecificas dirigidas al ligando tipo delta 3 (dll3).
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
MX2024011378A (es) Compuestos de urea triciclica como inhibidores de la variante v617f de la cinasa de janus 2 (jak2).
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
MX2025000777A (es) Heterociclos inhibidores de la nitrificacion
PH12022550497A1 (en) Perk inhibiting compounds
MX2024004874A (es) Compuestos heterociclicos para uso en el tratamiento de cancer.
MX2025000637A (es) Moleculas de union al antigeno anti-steap1 y sus usos
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2